	US RE50,682 E1
	Immunoglobulin variable domains
Marie-Ange Buyse, Merelbeke (BE); and Carlo Boutton, Wielsbeke (BE)
Assigned to Ablynx NV, Ghent-Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed by Ablynx N.V., Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed on Dec. 6, 2022, as Appl. No. 18/062,103.
Application 16/695,420 is a division of application No. 15/311,564, granted, now 12,180,268, previously published as PCT/EP2015/060643, filed on May 13, 2015.
Application 18/062,103 is a continuation of application No. 16/695,420, filed on Nov. 26, 2019, granted, now 11,312,764.
Application 18/062,103 is a reissue of application No. 17/215,163, filed on Mar. 29, 2021, granted, now 11,319,364, issued on May 3, 2022.
Claims priority of provisional application 62/133,600, filed on Mar. 16, 2015.
Claims priority of provisional application 62/047,560, filed on Sep. 8, 2014.
Claims priority of provisional application 62/040,167, filed on Aug. 21, 2014.
Claims priority of provisional application 62/014,015, filed on Jun. 18, 2014.
Claims priority of provisional application 61/994,552, filed on May 16, 2014.
Int. Cl. C07K 16/24 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C07K 16/42 (2006.01)

CPC C07K 16/18 (2013.01) [C07K 16/00 (2013.01); C07K 16/24 (2013.01); C07K 16/241 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 16/42 (2013.01); C07K 16/4291 (2013.01)]

15 Claims

1. A heavy chain immunoglobulin single variable domain (ISVD) in which the amino acid residue at Kabat position 11 is V and the amino acid residue at Kabat position 89 is L, wherein the heavy chain ISVD specifically binds to:

(A) IL-23 and comprises:

(i) a CDR1 sequence that is the sequence of SEQ ID NO: 173; a CDR2 sequence that is the sequence of SEQ ID NO: 174; and a CDR3 sequence that is the sequence of SEQ ID NO: 175; or

(ii) a CDR1 sequence that is the sequence of SEQ ID NO: 191; a CDR2 sequence that is the sequence of SEQ ID NO: 192; and a CDR3 sequence that is the sequence of SEQ ID NO: 193;

(B) TNF and comprises:

a CDR1 sequence that is the sequence of SEQ ID NO: 335; a CDR2 sequence that is the sequence of SEQ ID NO: 336; and a CDR3 sequence that is the sequence of SEQ ID NO: 337.

[ 14. The heavy chain ISVD of claim 1, wherein the heavy chain ISVD specifically binds to IL-23 and comprises: a CDR1 sequence that is the sequence of SEQ ID NO: 173; a CDR2 sequence that is the sequence of SEQ ID NO: 174; and a CDR3 sequence that is the sequence of SEQ ID NO: 175. ]